TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Bavarian Nordic Announces Interim Results for the First Nine Months of 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bavarian Nordic A/S
Bavarian Nordic Announces Interim Results for the First Nine Months of 2025

Bavarian Nordic reported strong Q3 2025 financial results with 32% revenue increase, driven by Travel Health and Public Preparedness segments. The company launched its chikungunya vaccine Vimkunya globally and secured a new EU vaccine procurement contract.

Insights
KVUE   positive

Stock surged 20.04% with the acquisition, receiving $6.8 billion in upfront cash consideration


HRSPY   neutral

Signed a framework agreement with Bavarian Nordic for vaccine procurement without significant additional context